Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus

14 décembre 2007 mis à jour par: University of Pittsburgh

Three-Tracer PET Quantitation of Insulin Action in Muscle

The purpose of this research is to use a recently developed triple-tracer positron emission tomography (PET) method to study skeletal muscle insulin resistance. Insulin is the hormone made by your body to control the blood sugar level. "Resistance' to insulin could cause poor blood glucose control (blood sugar levels that are higher than normal). We want to use this new method to image (look at) the following three things: 1) how insulin affects blood flow in skeletal muscle 2) how insulin affects glucose (sugar) transport (movement) into muscle, and 3) how insulin affects glucose metabolism (breakdown) in skeletal muscle of healthy individuals.

PET imaging is a relatively non-invasive way to obtain a "metabolic picture" of body organs and has been used successfully to study brain, heart and more recently skeletal muscle. In this research study, we will use PET, with three radioactive tracers (markers), to study skeletal muscle glucose transport in individuals with type 2 diabetes mellitus (type 2 DM) and in non-diabetic individuals who are either normal weight or overweight/obese

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

The goal of this proposal is to use a recently developed triple-tracer positron emission tomography (PET) method to study skeletal muscle insulin resistance (IR) in research volunteers with type 2 diabetes mellitus (type 2 DM) and in comparison to age and gender-matched, normal weight non-diabetic volunteers, and in comparison to age, gender, and weight-matched overweight or obese non-diabetic volunteers. We will use the three tracers to obtain data on the respective insulin actions upon tissue perfusion, glucose transport and glucose phosphorylation in order to test the hypothesis that insulin resistance (IR) in type 2 DM is caused by an aggregation of impairments at these steps, thus challenging the prevalent concept that IR derives from a solitary impairment in trans-membrane transport.

Proximal steps of glucose transport and phosphorylation are considered to contribute strongly to the pathogenesis of IR in obesity and type 2 DM (1-5). These scientific considerations might have potential therapeutic implications. The overall goal of this project is to provide clarity in separating the respective roles of these proximal steps of glucose metabolism. Glucose transport will be assessed using 11C-3-O-methyl glucose (half-life ~ 20 min; also referred to as 3-0-MG), an analog that is transported but not phosphorylated. 18F-2-deoxy-2-fluoro-glucose (half-life ~ 109 min; also referred to as FDG), will be used to assess glucose transport and glucose phosphorylation. The third tracer that will be used, 15O-H2O, will provide information on tissue perfusion. The challenge with the use of FDG to study insulin action in muscle has been to derive data on two biochemical steps from the tissue activity pattern of a single tracer; this has placed a higher reliance upon the modeling of the data. However, in this project, because of the use of three tracers and the differences in the metabolism of the two glucose analogs, we will be able to address with clear resolution the respective roles of transport and phosphorylation in the pathogenesis of IR in obesity and type 2 DM.

Type d'étude

Observationnel

Inscription

24

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15213
        • University of Pittsburgh

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

30 ans à 55 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • We will recruit eight normal weight (BMI 19 to 25 kg/m2), and eight overweight or obese (BMI 27 to 38 kg/m2), non-diabetic, healthy volunteers, who are between the ages of 30 to 55 years old. For scientific reasons it is crucial that the groups are age matched. Limiting the age range to a period of 25 years will help achieve this goal. Volunteers for these two groups must have a fasting glucose < 110 mg/dl; HbA1c < 6.0%; Hct > 34; ALT < 60; AST < 60; Alk phos < 150; sTSH < 8; Trig < 300; Chol < 250; systolic BP < 150; diastolic BP < 95; and be in good health. A medical history and physical exam will be conducted by a nurse practitioner or a medical doctor.

We will also recruit eight volunteers with type 2 DM; as the large majority of this patient population is overweight or obese, inclusion criteria will include BMI 27 to 38 kg/m2, and otherwise age- and gender-matched to the non-diabetic volunteers. At screening, HbA1c must be less than 8.5%. For scientific purposes we would like to study the volunteers with type 2 DM without the confounding effects of anti-diabetic medications, therefore, we propose to restrict recruitment to those who are either treated by diet and exercise alone, or to those who are on oral agents in the sulfonylurea class, metformin, or acarbose.

Exclusion Criteria:

  • We will exclude volunteers taking thiazolidinediones as the washout period for this class is uncertain, and exclude those taking insulin as withdrawal likely would cause unacceptable levels of hyperglycemia.

Research volunteers with type 2 DM who are enrolled in the study and who are receiving oral diabetic agents (sulfonylureas, metformin or acarbose), will be instructed to withhold these medications for five days preceding both PET studies.

Previous difficulty with lidocaine (xylocaine) will be an exclusion. To be eligible for these studies, volunteers must be free of clinical evidence of cardiac, renal, hepatic, and vascular disease, or other major medical problems that would endanger the volunteers or compromise the scientific validity of the studies. Subjects with a history of myocardial infarction, proteinuria (defined as 1+ protein), alcohol or drug abuse, malignancy or neuromuscular disease will be excluded. Subjects who have gained or lost more than 3 kg during the past 3 months will be excluded. Because of the PET, MR, and DEXA scanning, all premenopausal women must have a negative pregnancy test within 24 hours prior to these procedures. To avoid radiation exposure of the infant, women who are currently breastfeeding will not be permitted to participate in this research study. Subjects will be excluded if they have a contraindication to MRI such as surgical or vascular implants, pregnancy, pacemaker, or claustrophobia. In subjects with a questionable history of metallic fragments, an X-ray of the suspected area of the body will be performed to rule such out.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Compare triple tracer PET imaging of skeletal muscle in lean, obese and T2DM

Mesures de résultats secondaires

Mesure des résultats
Mathematical modeling of PET data.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: David E Kelley, MD, University of Pittsburgh

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 janvier 2004

Achèvement de l'étude

1 décembre 2006

Dates d'inscription aux études

Première soumission

19 septembre 2005

Première soumission répondant aux critères de contrôle qualité

19 septembre 2005

Première publication (Estimation)

22 septembre 2005

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

19 décembre 2007

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 décembre 2007

Dernière vérification

1 décembre 2007

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 0311010
  • R01DK060555 (Subvention/contrat des NIH des États-Unis)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

3
S'abonner